Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H16N2S.ClH |
| Molecular Weight | 268.805 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H](C1=CNC(=S)N1)C2=CC=CC(C)=C2C
InChI
InChIKey=FKVKHBODOZRGOP-PPHPATTJSA-N
InChI=1S/C13H16N2S.ClH/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12;/h4-7,10H,1-3H3,(H2,14,15,16);1H/t10-;/m0./s1
Rezatomidine (AGN 203818) is an alpha adrenergic receptor agonist that was developed for the treatment of chronic pain conditions. Phase II studies have evaluated the safety and effectiveness of rezatomidine in treating the pain in patients with fibromyalgia, irritable bowel syndrome, interstitial cystitis, and diabetic neuropathy. However, three studies were terminated early based on a business decision. Pancreatitis, gastric ulcer, viral infections and dehydration were reported as serious adverse events in patients when administered a 60mg dose.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1021954-16-4
Created by
admin on Mon Mar 31 18:42:02 GMT 2025 , Edited by admin on Mon Mar 31 18:42:02 GMT 2025
|
PRIMARY | |||
|
1C25MR0H0E
Created by
admin on Mon Mar 31 18:42:02 GMT 2025 , Edited by admin on Mon Mar 31 18:42:02 GMT 2025
|
PRIMARY | |||
|
76970479
Created by
admin on Mon Mar 31 18:42:02 GMT 2025 , Edited by admin on Mon Mar 31 18:42:02 GMT 2025
|
PRIMARY | |||
|
DBSALT002143
Created by
admin on Mon Mar 31 18:42:02 GMT 2025 , Edited by admin on Mon Mar 31 18:42:02 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
